177 Lu PSMA 617 - RadioMedix/Excel diagnostics

Drug Profile

177 Lu PSMA 617 - RadioMedix/Excel diagnostics

Alternative Names: 177 Lu PSMA-617

Latest Information Update: 02 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RadioMedix
  • Developer Excel Diagnostics and Nuclear Oncology Center; RadioMedix; University of California at Los Angeles; University of Freiburg
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 11 Apr 2017 Phase-II clinical trials in Prostate cancer (Metastatic disease) in USA (IV) (NCT03042312)
  • 10 Feb 2017 Radiomedix plans a phase II trial for Prostate cancer (Metastatic disease) in USA (NCT03042312)
  • 07 Feb 2017 Preclinical trial in Prostate cancer (Metastatic disease) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top